Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of biomarkers for response to radium-223 in metastatic castration-resistant prostate cancer
2013-004055-20Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Sep 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Bone metastases response on diffusion-weighted MRI. Status: unknown.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2013-004055-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004055-20.